The FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections (uUTIs) ...

The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial ...

The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...

Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...

FDA approves new oral antibiotic for uncomplicated urinary tract infections in women with limited treatment options. Orylnvah shows superior response rates ...

ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades--Company ...

The "Salivary Gland Infection Market Report Global Forecast by Type, Application, Country and Company Analysis 2024-2032" ...

The US Food and Drug Administration (FDA) has approved Iterum Therapeutics' new drug application (NDA) for ORLYNVAH ...